Stocktoria
INSULET CORP PODD
INSULET CORP (PODD) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $2.7B at a 9.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-06 | Canaccord Genuity | Buy (main) |
| 2026-08-06 | Leerink Partners | Market Perform (down) |
| 2026-08-06 | TD Cowen | Hold (main) |
| 2026-08-06 | UBS | Neutral (main) |
| 2026-08-06 | RBC Capital | Outperform (main) |
| 2026-08-06 | Bernstein | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.387 |
| Retained earnings / assets | 0.09 |
| EBIT / assets | 0.149 |
| Equity / liabilities | 0.904 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PODD | INSULET CORP | 6/9 | 4.78 | 44.4 | +30.7% |
| GMED | GLOBUS MEDICAL INC | 7/9 | 10.06 | 21.8 | +16.7% |
| WST | WEST PHARMACEUTICAL SERVICES INC | 7/9 | 9.34 | 47.2 | +6.3% |
| MMED | MiniMed Group, Inc. | 3/9 | 4.28 | — | +14.3% |
| ICUI | ICU MEDICAL INC/DE | 6/9 | 2.9 | — | -6.3% |
| TFX | TELEFLEX INC | 5/9 | 3.56 | — | +17.2% |
| IART | INTEGRA LIFESCIENCES HOLDINGS CORP | 5/9 | 1.17 | — | +1.5% |
About INSULET CORP
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
FAQ
Is PODD financially healthy?
INSULET CORP's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does PODD pay a dividend?
No, INSULET CORP does not currently pay a dividend.
How profitable is PODD?
In FY2025, INSULET CORP had a net margin of 9.1% and a return on equity of 16.3%.
Is PODD overvalued or undervalued?
INSULET CORP trades at about 41.7× trailing earnings — below its 10-year norm (10-year range 48.2×–4104.6×, median 1033.3×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for PODD?
The average Wall-Street price target for INSULET CORP is $171.91, about 18.5% above the recent price, from 22 analysts (consensus: buy).
Is PODD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on INSULET CORP: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 44.4×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.